Novavax said on Tuesday it signed a licensing agreement allowing Pfizer access to its technology that boosts immune ...
Pfizer has signed a deal worth up to $530m with US-based vaccine technology company Novavax. This agreement will see Pfizer ...
Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...
Zacks Investment Research on MSN
Novavax grants license for use of Matrix-M adjuvant to Pfizer
Novavax NVAX announced a non-exclusive license agreement with Pfizer PFE, granting the latter access to its proprietary ...
Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
Novavax said on Tuesday it was entering into a licensing agreement with Pfizer to develop vaccine products for ...
Meanwhile, during the WSJ event in Davos this week, Pfizer’s Bourla also took aim at the Trump administration’s moves to cut ...
Novavax, the Covid-19 vaccine maker, has licensed the rights for a vaccine-enhancing component to Pfizer. Pfizer agreed to pay $30 million upfront, and could pay up to $500 million more if development ...
An analysis of safety data suggests that Abrysvo, the Pfizer respiratory syncytial virus (RSV) RSVpreF vaccine, does not ...
Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback